BLUEBIRD BIO INC (BLUE) Stock Price & Overview
NASDAQ:BLUE • US09609G2093
Current stock price
The current stock price of BLUE is 4.97 USD. Today BLUE is down by 0%. In the past month the price increased by 22.72%. In the past year, price decreased by -72.49%.
BLUE Key Statistics
- Market Cap
- 48.656M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -20.53
- Dividend Yield
- N/A
BLUE Stock Performance
BLUE Stock Chart
BLUE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BLUE. When comparing the yearly performance of all stocks, BLUE is a bad performer in the overall market: 88.09% of all stocks are doing better.
BLUE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BLUE. Both the profitability and financial health of BLUE have multiple concerns.
BLUE Earnings
On May 14, 2025 BLUE reported an EPS of -2.98 and a revenue of 38.71M. The company beat EPS expectations (25.85% surprise) and beat revenue expectations (0.87% surprise).
BLUE Forecast & Estimates
10 analysts have analysed BLUE and the average price target is 8.84 USD. This implies a price increase of 77.87% is expected in the next year compared to the current price of 4.97.
For the next year, analysts expect an EPS growth of 52.54% and a revenue growth 199.26% for BLUE
BLUE Groups
Sector & Classification
BLUE Financial Highlights
Over the last trailing twelve months BLUE reported a non-GAAP Earnings per Share(EPS) of -20.53. The EPS increased by 58.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BLUE Ownership
BLUE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.49 | 384.559B | ||
| AMGN | AMGEN INC | 15.48 | 189.672B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 173.017B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.07 | 113.435B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 81.684B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.06 | 43.88B | ||
| INSM | INSMED INC | N/A | 35.247B | ||
| NTRA | NATERA INC | N/A | 28.345B | ||
| BIIB | BIOGEN INC | 11.43 | 26.906B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 25.99B | ||
| MRNA | MODERNA INC | N/A | 20.063B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.272B | ||
| INCY | INCYTE CORP | 12.31 | 18.731B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BLUE
Company Profile
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. The company is headquartered in Somerville, Massachusetts and currently employs 248 full-time employees. The company went IPO on 2013-06-19. The firm is focused on researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The company markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA is used for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).
Company Info
IPO: 2013-06-19
BLUEBIRD BIO INC
455 Grand Union Boulevard
Somerville MASSACHUSETTS 02142 US
CEO: Nick Leschly
Employees: 248
Phone: 13394999300
BLUEBIRD BIO INC / BLUE FAQ
What does BLUE do?
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. The company is headquartered in Somerville, Massachusetts and currently employs 248 full-time employees. The company went IPO on 2013-06-19. The firm is focused on researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The company markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA is used for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).
Can you provide the latest stock price for BLUEBIRD BIO INC?
The current stock price of BLUE is 4.97 USD.
What is the dividend status of BLUEBIRD BIO INC?
BLUE does not pay a dividend.
What is the ChartMill technical and fundamental rating of BLUE stock?
BLUE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for BLUE stock?
10 analysts have analysed BLUE and the average price target is 8.84 USD. This implies a price increase of 77.87% is expected in the next year compared to the current price of 4.97.
Can you provide the market cap for BLUEBIRD BIO INC?
BLUEBIRD BIO INC (BLUE) has a market capitalization of 48.66M USD. This makes BLUE a Nano Cap stock.
Can you provide the ownership details for BLUE stock?
You can find the ownership structure of BLUEBIRD BIO INC (BLUE) on the Ownership tab.